CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN

505(b)(2) Clinical Trials for CIPROFLOXACIN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01168895 ↗	Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder	Completed	Bayer	Phase 1	2010-07-01	The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients. In this study the 48.75 mg dose will be administered for the first time using a new high dose strength (i.e. one capsule containing 75 mg powder = 48.75 mg ciprofloxacin) formulation. Safety investigations will focus on local tolerability in the lung and evaluate whether the patient can inhale the higher amount of powder compared to the lower dose strength. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug. Results from this study will be used to decide whether the new dose strength is suitable for larger clinical trials planned for the COPD patients population.

All Clinical Trials for CIPROFLOXACIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000641 ↗	A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To compare the effectiveness and toxicity of two combination drug treatment programs for the treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per 03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is the most common systemic bacterial infection complicating AIDS in the United States. The prognosis of patients with disseminated M. avium is extremely poor, particularly when it follows other opportunistic infections or is associated with anemia. Test tube studies and clinical data indicate that the best treatment program may include clofazimine, ethambutol, a rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that amikacin is a bactericidal (bacteria destroying) drug that works better when used with ciprofloxacin. Its role in treatment programs is a key issue because of toxicity and because it must be administered parenterally (by injection or intravenously).
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	Eastern Cooperative Oncology Group	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	Gary Morrow	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00003407 ↗	Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia	Unknown status	National Cancer Institute (NCI)	Phase 2	1998-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine and high-dose combination chemotherapy in treating patients with acute myeloid leukemia or chronic myelogenous leukemia.

Clinical Trial Conditions for CIPROFLOXACIN

Condition Name

Condition Name for CIPROFLOXACIN
Intervention	Trials
Urinary Tract Infections	17
Healthy	12
Infection	8
Pouchitis	7

Condition MeSH

Condition MeSH for CIPROFLOXACIN
Intervention	Trials
Infections	47
Infection	39
Communicable Diseases	36
Urinary Tract Infections	34

Clinical Trial Locations for CIPROFLOXACIN

Trials by Country

Trials by Country for CIPROFLOXACIN
Location	Trials
United States	509
Germany	44
United Kingdom	43
Spain	43
Canada	39

Trials by US State

Trials by US State for CIPROFLOXACIN
Location	Trials
Texas	33
California	32
Florida	27
North Carolina	24
New York	23

Clinical Trial Progress for CIPROFLOXACIN

Clinical Trial Phase

Clinical Trial Phase for CIPROFLOXACIN
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	4
PHASE2	9

Clinical Trial Status

Clinical Trial Status for CIPROFLOXACIN
Clinical Trial Phase	Trials
Completed	174
Recruiting	46
Not yet recruiting	30

Clinical Trial Sponsors for CIPROFLOXACIN

Sponsor Name

Sponsor Name for CIPROFLOXACIN
Sponsor	Trials
Bayer	23
National Institute of Allergy and Infectious Diseases (NIAID)	8
PriCara, Unit of Ortho-McNeil, Inc.	6

Sponsor Type

Sponsor Type for CIPROFLOXACIN
Sponsor	Trials
Other	388
Industry	146
NIH	20

Last updated: April 23, 2026

Ciprofloxacin: Clinical-Stage Status, Market Economics, and Forward Projection

Where is ciprofloxacin in the clinical pipeline?

Ciprofloxacin is an established generic small-molecule antibiotic with widespread commercial use; no company-sponsored late-stage development that would materially change the market is identifiable as a discrete, current clinical trial “program” from the record available here. The practical clinical-trials landscape for ciprofloxacin is therefore dominated by:

• Post-marketing, label-expansion, and comparative studies for existing indications and formulations.
• Generic bioequivalence trials required for market authorization.
• Resistance and stewardship-related observational research.

No new, clearly named, ongoing phase-defining “ciprofloxacin new drug application” programs are captured in the provided evidence base for this report.

---

What does the ciprofloxacin market look like today?

Ciprofloxacin sits in the systemic antibacterials category where demand is driven by:

• Acute bacterial infections in outpatient and hospital settings.
• Guideline-concordant prescribing across respiratory, urinary tract, and gastrointestinal indications.
• Relative pricing pressure from generics and form-factor-specific competition (tablets, IV, ophthalmic, otic, and extended-release where applicable).

Market structure

• Generic dominance: ciprofloxacin is widely available in multiple strengths and routes. This suppresses branded-like pricing power and turns market outcomes into a share-and-volume game.
• Formulation fragmentation: IV and oral drive most system-wide consumption; ophthalmic/otic products add niche volume.
• Regional prescribing differences: antibiotic use patterns vary by country and payor stewardship rules.

Key demand constraints

• Antimicrobial resistance: limits clinical effectiveness and increases the likelihood of switching to alternatives.
• Stewardship restrictions: impacts fluoroquinolone prescribing intensity in some systems.
• Safety labeling and clinician preference: fluoroquinolone class safety concerns influence choice for borderline indications, pushing use toward more severe or guideline-supported settings.

---

How big is ciprofloxacin, and what is the forecast direction?

Because ciprofloxacin is commoditized and data coverage for a single monograph drug market is fragmented across sources, the most decision-relevant projection is framed as trend direction and drivers rather than a single-point “global sales” number. The direction is driven by a balance of:

• Stable baseline demand from standard-of-care use in UTIs and select bacterial respiratory infections.
• Pressure from resistance and stewardship that caps growth.
• Substitution within antibacterials where newer agents (or other fluoroquinolones, cephalosporins, carbapenems, macrolides, etc.) win protocol-based shares.

Projection

• Short-to-medium term (next ~3-5 years): flat-to-low growth in value terms due to generic pricing and procurement competitiveness; volume may hold up but is unlikely to compound strongly unless resistance patterns and guideline updates expand use in specific indications.
• Longer term (5-10 years): continued maturity. Growth is more likely to come from route/formulation mix and regional formulary inclusion than from new clinical breakthroughs.

This forecast posture aligns with broad market realities for generic systemic antibiotics: value growth is limited; share capture and compliance with local tender and formulary rules dominate.

---

What are the main commercial drivers for ciprofloxacin over the next cycle?

1) Formulary access and tender economics

• In many health systems, ciprofloxacin competes on tender price, product availability, and line-item compliance.
• Winners typically maintain manufacturing continuity and pass bioequivalence/quality requirements without disruptions.

2) Resistance and guideline dynamics

• Resistance reduces effective cure rates, which can shift prescribing toward other agents.
• Clinical guidelines that narrow fluoroquinolone indications curb overall class exposure; ciprofloxacin benefit then depends on whether it remains a recommended option for key syndromes.

3) Safety and utilization management

• Class safety communications affect clinician behavior.
• Stewardship programs reduce “low-severity” use, which impacts demand in marginal indications.

4) Supply chain and manufacturing capacity

• Generic antibiotics are sensitive to capacity shocks and API availability.
• Exchangeability among generics keeps pricing elastic to supply.

---

What is the investment-grade outlook by use case?

Hospital (IV/oral)

• Demand tends to be more stable where ciprofloxacin is preferred for specific resistant Gram-negative scenarios.
• Protocol-driven use persists but can be competed away by alternatives if outcomes data or local resistance profiles favor other classes.

Outpatient (oral)

• Volume is more exposed to stewardship and prescriber choice.
• Growth is less likely where prescribers pivot to other guideline-supported agents.

Ophthalmic/otic niches

• These can sustain steadier relative demand because the use case is narrower and product formats differ more from systemic competition.

Overall, near-term value growth is most plausibly driven by mix (route/formulation and contract pricing outcomes) rather than market expansion.

---

How should a decision-maker project ciprofloxacin revenue realistically?

A revenue model that holds up for commoditized antibiotics should be structured around:

• Price: tender-based, generic-driven; expect mean reversion downward unless supply constraints tighten.
• Volume: anchored by infection epidemiology and antibiotic prescribing rates; limited upside without guideline expansions.
• Share: dependent on manufacturing uptime, regulatory compliance, and distribution relationships.
• Mix: IV vs oral vs ophthalmic/otic determines margins and can offset price compression.

A practical projection pattern is:

• Value growth = (volume growth) + (mix shift toward higher-margin formats) - (price erosion).
• In most mature generic environments, price erosion offsets modest volume changes.

---

Key Takeaways

• Ciprofloxacin remains a mature, generic small-molecule antibiotic with commercial dynamics dominated by formulary access, tender pricing, and stewardship constraints, not new clinical differentiation.
• The clinical-trials landscape is largely post-marketing and bioequivalence/comparative evidence, with limited signposting of phase-defining new development programs in the provided record.
• The market outlook is flat-to-low growth in value over the next 3-5 years, with the highest upside tied to mix shifts and regional share capture, not broad demand expansion.
• Projections should be built on price-volume-share-mix mechanics given the commoditized nature of ciprofloxacin and its susceptibility to procurement economics.

---

FAQs

1. Is ciprofloxacin still prescribed for UTIs and respiratory infections?
   Yes, but utilization depends on guideline inclusion and local resistance profiles; stewardship programs can narrow use.

2. What most affects ciprofloxacin sales in the near term: volume or price?
   Price typically dominates because generic procurement drives downward pressure, while volume tends to be steadier unless clinical practice changes materially.

3. Do safety and antimicrobial resistance reduce ciprofloxacin demand?
   They can reduce use in borderline indications and shift prescribing toward alternatives, limiting growth.

4. What are the levers for gaining market share in ciprofloxacin?
   Regulatory compliance, manufacturing uptime, reliable supply, and favorable tender/formulary positioning.

5. Is there a credible pathway for significant market value growth without new indications?
   Yes, but it is usually incremental via product mix (route/formulation), contract wins, and regional share, not via step-change clinical innovation.

---

References

[1] U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[3] World Health Organization. Antibacterial agents in clinical use and antimicrobial resistance resources. https://www.who.int/health-topics/antimicrobial-resistance/
[4] European Medicines Agency. Medicine information and assessment resources. https://www.ema.europa.eu/